Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
July 13 2020 - We have already submitted notification to the U.S. Food and Drug Administration that we intend to commence commercial distribution of the SARS-CoV-2 IgG immunoassay test later this month.
Have we not received any 'robust' & 'synergistic' update on this small bit of information?
HGEN 9.77 - interesting. How many other SEC-compliant-stocks do we know of that have a covid-therapeutic in Phase 3?
Humanigen expects to complete the targeted enrollment of 300 patients this month with topline data available in the fourth quarter.
https://www.humanigen.com/press/Humanigen-Announces-Review-of-Lenzilumab-Phase-3-Study-in-COVID-19-by-Data-Safety-Monitoring-Board
"...evidence shows that officers both knocked and announced their presence..."
Candace Owens 100% gets it...
New website and @twitter:
https://beamforall.com/
https://twitter.com/BeamForAll
i.e. raise the damn prices! These save-all-mankind Gavin Newsom's and Bill DeBlasio's don't care how much taxpayer money they blow...come to think of it...do any of our politician's really care about blowing cash of which they have not...
New pump to sell stock -
https://www.proactiveinvestors.com/companies/news/929543/beam-global-officially-changes-its-name-from-envision-solar-to-more-accurately-reflect-its-activities-929543.html
In exchange for publishing services rendered by the Company on behalf of Beam Global named herein, including the promotion by the Company of Beam Global in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars ($25,000).
Will they ever, Ever, EVER make selling PRODUCT their primary focus?
BEEM is the new symbol.
APT 14.30 - added some yesterday at this pps and wrote the Oct.2-$15 calls at .55.
I've adopted somewhat of a 'takin what they're givin' strategy on these waayyyyyy over-lucrative covered calls as I expect this insane-callwrite-lucrativity will vanish anyday now...
BGFV 6.14 - several days ago, I wrote the Oct.-7.50 calls at .50...
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=157622709
...and just a few days ago, I added at 5.65 and subsequently wrote the Oct.-5.00 calls at 1.35.
You'll hear ZERO whining from me re:BGFV...
Seriously, Clark!
SNFCA 6.34 - ditto - "Haven't seen a stock like this one in a long time, if you have other names like this one, don't feel shy to share."
NBIO .063 - Nascent Biotech Research Collaboration Partner, Manhattan BioSolutions, Receives Grant for Covid 19 Vaccine Studies.
Wednesday, September 23, 2020 8:00 AM
Share this article now
Topic: Company Update
SAN DIEGO, CA / ACCESSWIRE / September 23, 2020 / Nascent Biotech, Inc (OTCQB:NBIO), a biotechnology company pioneering innovative medicines to overcome difficult-to-treat cancers and viral infections, announces that its collaboration partner, Manhattan BioSolutions, has been awarded a Phase I SBIR grant by the National Science Foundation (NSF) entitled "Genetically Engineered BCG as a Microbe-Based Platform for Vaccination Against COVID-19".
The grant will support early discovery research with the goal to develop safe and affordable COVID-19 vaccination platform based on the licensed vaccine against tuberculosis (TB), with broader utility in preventing other types of viruses that may cause major outbreaks in humans. Under the agreement signed earlier in May 2020, Nascent Biotech and Manhattan BioSolutions have partnered to advance selected vaccine candidates to late-stage preclinical development.
This novel vaccination technology is based on the genetically modified bacteria Bacillus Calmette-Guérin (BCG), which has a long safety track record as a highly cost-effective vaccine against TB used in infants and small children. BCG vaccination has been shown to produce beneficial heterologous immune mechanisms leading to improved response against infections; The proposed project enables the generation of a new class of live bacterial therapeutics engineered to specifically target SARS-CoV-2 and induce trained immunity in humans, with the potential to protect against COVID-19 disease and its associated pathology.
Dr. Boris Shor, CEO of Manhattan BioSolutions, added: "This project is built upon our prior expertise designing therapeutic vaccine candidates for oncology indications; it is also complementary to our core efforts to discover innovative therapeutic agents targeting pathogen-related immunity for the treatment of cancer.
Sean Carrick, CEO of Nascent Biotech commented: "Published evidence suggests that BCG vaccination is safe and might be associated with a decrease in the incidence of sickness during the COVID-19 pandemic, and lower incidence of extreme fatigue The award of this grant furthers the objective of building a Viral Infection business platform and providing meaningful treatment for patients. We are excited to be working together with Manhattan BioSolutions with the goal to deliver innovative therapies that can change patients' lives.
About Manhattan BioSolutions
Manhattan BioSolutions, Inc. is a privately held biotechnology company focused on the discovery and development of immunotherapies that target innate immunity for the treatment of cancer and inflammatory diseases. MBS leverages two technology platforms for drug discovery: microbial based genetically engineered immune stimulator platform, and monoclonal antibodies against innate immune sensors that recognize pathogens or endogenous "danger signals" released as a result of tissue injury or inflammation.
About Nascent Biotech
Nascent Biotech, Inc. (OTCQB: NBIO) is a clinical-stage biotech company pioneering the development of monoclonal antibodies to be used in the treatment of various cancers and viral infections helping millions of people worldwide. Its products are not commercially available. For further information please visit our website www.nascentbiotech.com. Our lead candidate, Pritumumab (PTB), is a monoclonal Antibody (Mab) will be studied in Phase I clinical trial later this year for the treatment of Brain Cancer. Development for PTB as a treatment for COVID-19 has been initiated. For more information, visit www.nascentbiotech.com.
https://www.accesswire.com/607322/Nascent-Biotech-Research-Collaboration-Partner-Manhattan-BioSolutions-Receives-Grant-for-Covid-19-Vaccine-Studies
NBIO .063 - Nascent Biotech Research Collaboration Partner, Manhattan BioSolutions, Receives Grant for Covid 19 Vaccine Studies.
Wednesday, September 23, 2020 8:00 AM
Share this article now
Topic: Company Update
SAN DIEGO, CA / ACCESSWIRE / September 23, 2020 / Nascent Biotech, Inc (OTCQB:NBIO), a biotechnology company pioneering innovative medicines to overcome difficult-to-treat cancers and viral infections, announces that its collaboration partner, Manhattan BioSolutions, has been awarded a Phase I SBIR grant by the National Science Foundation (NSF) entitled "Genetically Engineered BCG as a Microbe-Based Platform for Vaccination Against COVID-19".
The grant will support early discovery research with the goal to develop safe and affordable COVID-19 vaccination platform based on the licensed vaccine against tuberculosis (TB), with broader utility in preventing other types of viruses that may cause major outbreaks in humans. Under the agreement signed earlier in May 2020, Nascent Biotech and Manhattan BioSolutions have partnered to advance selected vaccine candidates to late-stage preclinical development.
This novel vaccination technology is based on the genetically modified bacteria Bacillus Calmette-Guérin (BCG), which has a long safety track record as a highly cost-effective vaccine against TB used in infants and small children. BCG vaccination has been shown to produce beneficial heterologous immune mechanisms leading to improved response against infections; The proposed project enables the generation of a new class of live bacterial therapeutics engineered to specifically target SARS-CoV-2 and induce trained immunity in humans, with the potential to protect against COVID-19 disease and its associated pathology.
Dr. Boris Shor, CEO of Manhattan BioSolutions, added: "This project is built upon our prior expertise designing therapeutic vaccine candidates for oncology indications; it is also complementary to our core efforts to discover innovative therapeutic agents targeting pathogen-related immunity for the treatment of cancer.
Sean Carrick, CEO of Nascent Biotech commented: "Published evidence suggests that BCG vaccination is safe and might be associated with a decrease in the incidence of sickness during the COVID-19 pandemic, and lower incidence of extreme fatigue The award of this grant furthers the objective of building a Viral Infection business platform and providing meaningful treatment for patients. We are excited to be working together with Manhattan BioSolutions with the goal to deliver innovative therapies that can change patients' lives.
About Manhattan BioSolutions
Manhattan BioSolutions, Inc. is a privately held biotechnology company focused on the discovery and development of immunotherapies that target innate immunity for the treatment of cancer and inflammatory diseases. MBS leverages two technology platforms for drug discovery: microbial based genetically engineered immune stimulator platform, and monoclonal antibodies against innate immune sensors that recognize pathogens or endogenous "danger signals" released as a result of tissue injury or inflammation.
About Nascent Biotech
Nascent Biotech, Inc. (OTCQB: NBIO) is a clinical-stage biotech company pioneering the development of monoclonal antibodies to be used in the treatment of various cancers and viral infections helping millions of people worldwide. Its products are not commercially available. For further information please visit our website www.nascentbiotech.com. Our lead candidate, Pritumumab (PTB), is a monoclonal Antibody (Mab) will be studied in Phase I clinical trial later this year for the treatment of Brain Cancer. Development for PTB as a treatment for COVID-19 has been initiated. For more information, visit www.nascentbiotech.com.
https://www.accesswire.com/607322/Nascent-Biotech-Research-Collaboration-Partner-Manhattan-BioSolutions-Receives-Grant-for-Covid-19-Vaccine-Studies
Nascent Biotech Research Collaboration Partner, Manhattan BioSolutions, Receives Grant for Covid 19 Vaccine Studies.
Wednesday, September 23, 2020 8:00 AM
Share this article now
Topic: Company Update
SAN DIEGO, CA / ACCESSWIRE / September 23, 2020 / Nascent Biotech, Inc (OTCQB:NBIO), a biotechnology company pioneering innovative medicines to overcome difficult-to-treat cancers and viral infections, announces that its collaboration partner, Manhattan BioSolutions, has been awarded a Phase I SBIR grant by the National Science Foundation (NSF) entitled "Genetically Engineered BCG as a Microbe-Based Platform for Vaccination Against COVID-19".
The grant will support early discovery research with the goal to develop safe and affordable COVID-19 vaccination platform based on the licensed vaccine against tuberculosis (TB), with broader utility in preventing other types of viruses that may cause major outbreaks in humans. Under the agreement signed earlier in May 2020, Nascent Biotech and Manhattan BioSolutions have partnered to advance selected vaccine candidates to late-stage preclinical development.
This novel vaccination technology is based on the genetically modified bacteria Bacillus Calmette-Guérin (BCG), which has a long safety track record as a highly cost-effective vaccine against TB used in infants and small children. BCG vaccination has been shown to produce beneficial heterologous immune mechanisms leading to improved response against infections; The proposed project enables the generation of a new class of live bacterial therapeutics engineered to specifically target SARS-CoV-2 and induce trained immunity in humans, with the potential to protect against COVID-19 disease and its associated pathology.
Dr. Boris Shor, CEO of Manhattan BioSolutions, added: "This project is built upon our prior expertise designing therapeutic vaccine candidates for oncology indications; it is also complementary to our core efforts to discover innovative therapeutic agents targeting pathogen-related immunity for the treatment of cancer.
Sean Carrick, CEO of Nascent Biotech commented: "Published evidence suggests that BCG vaccination is safe and might be associated with a decrease in the incidence of sickness during the COVID-19 pandemic, and lower incidence of extreme fatigue The award of this grant furthers the objective of building a Viral Infection business platform and providing meaningful treatment for patients. We are excited to be working together with Manhattan BioSolutions with the goal to deliver innovative therapies that can change patients' lives.
About Manhattan BioSolutions
Manhattan BioSolutions, Inc. is a privately held biotechnology company focused on the discovery and development of immunotherapies that target innate immunity for the treatment of cancer and inflammatory diseases. MBS leverages two technology platforms for drug discovery: microbial based genetically engineered immune stimulator platform, and monoclonal antibodies against innate immune sensors that recognize pathogens or endogenous "danger signals" released as a result of tissue injury or inflammation.
About Nascent Biotech
Nascent Biotech, Inc. (OTCQB: NBIO) is a clinical-stage biotech company pioneering the development of monoclonal antibodies to be used in the treatment of various cancers and viral infections helping millions of people worldwide. Its products are not commercially available. For further information please visit our website www.nascentbiotech.com. Our lead candidate, Pritumumab (PTB), is a monoclonal Antibody (Mab) will be studied in Phase I clinical trial later this year for the treatment of Brain Cancer. Development for PTB as a treatment for COVID-19 has been initiated. For more information, visit www.nascentbiotech.com.
https://www.accesswire.com/607322/Nascent-Biotech-Research-Collaboration-Partner-Manhattan-BioSolutions-Receives-Grant-for-Covid-19-Vaccine-Studies
APT 15.25 - up nicely on the buyback news and the callwrite premiums are once again lucrative.
Wrote a few 10-2/16.50's at $.60
APT 14.40 - ALPHA PRO TECH, LTD. ANNOUNCES $5 MILLION EXPANSION OF SHARE REPURCHASE PROGRAM
https://finance.yahoo.com/news/alpha-pro-tech-ltd-announces-130000662.html
July 28, 2020 - "This collaboration will determine if Pritumumab can effectively block SARS2 in an animal mouse model. It will also gauge Pritumumab's ability to bind vimentin in a live model."
https://finance.yahoo.com/news/nascent-biotech-announces-collaboration-syracuse-120000355.html
9/9/20 - Excited to share our review article on the life of vimentin - inside and outside the cell! Mechanical and Non-mechanical functions of filamentous and non-filamentous vimentin:
https://twitter.com/PattesonLab/status/1303735403061669888/photo/1
9/6/20 - 5 Conclusion
The striking viscoelastic properties of VIF networks in vitro suggest cellular functions based on resistance to mechanical stress and regulation of cell shape. Indeed VIFs are essential for protection of the nucleus from potentially damaging forces and forms much of the cytoskeleton. However, many studies point to important non-mechanical functions. Vimentin, either in the form of small oligomers or VIFs, binds numerous proteins and nucleic acids, and functions to integrate with other cytoskeletal systems, regulate lipid metabolism and perform numerous other intracellular functions. In addition, the rapidly growing study of extracellular vimentin, especially in the regulated disassembly of VIF and the secretion of modified vimentin, reveals many new functions for the protein, from mediating pathogen invasion to promoting wound healing. Clearly there is much more to be learned about this abundant but understudied protein.
https://onlinelibrary.wiley.com/doi/full/10.1002/bies.202000078
SNFCA 6.28 - seller decides to take a large dump on a Friday at the close?
https://bigcharts.marketwatch.com/quickchart/quickchart.asp?symb=snfca&insttype=&freq=9&show=&time=1
A bit odd - wonder what this seller is buying?
SNFCA 6.44 - the board-fav (BGFV) is making a nice, way overdue, move today with a "projected" $1 eps while our laggard, SNFCA, has already bagged a $1 eps...
https://old.nasdaq.com/symbol/snfca/revenue-eps
...makes one truly wonder about delusions of any market-efficiency whatsover?
Patiently sitting on a triple-down bid here at 6.33...
Watching yesterday's close, I noticed the first time in a loooonnnggggg time that the bid was not unmercifully pounded by the likeliest of our bid-pounding-culprits, 'in-lieu-of-pay-shareholders'.
Hallelujah, sure didn't take em long to realize that this LEGITIMATE - Phase 1 trial brain cancer, potential covid therapeutic, and potential covid vaccine - stock has dipped down to a $4M marketcap...
https://www.otcmarkets.com/stock/NBIO/profile
...in a vast ocean of LESSER peer stocks trading in the $BILLIONS$ marketcaps.
While we continue awaiting updates, got me some .06's and some .05's...anyone got any .04's?
NBIO .052 vs IPIX .23:
IPIX Market Cap - $72,197,016 - 09/14/2020
NBIO Market Cap - $4,002,740 - 09/14/2020
And imho, NBIO's fundamentals blow away the fundamentals of IPIX!
IPIX - a search at the Gilead website shows nada...
https://www.gilead.com/utility/search?q=Brilacidin
ABUS 2.94 - "Arbutus Announces AB-729 90 mg Single-Dose Week 12 Data in Chronic Hepatitis B Subjects Demonstrating Significant and Continuous Reductions in HBsAg"
https://finance.yahoo.com/news/arbutus-announces-ab-729-90-113000767.html
I still believe ABUS is a low-risk investment at under-$4 pps as a stand-alone...excluding...the absolute rocketship potential here if/WHEN it's "069-Patent" makes the 6:00 0'clock news...
ABUS 2.94 - "Arbutus Announces AB-729 90 mg Single-Dose Week 12 Data in Chronic Hepatitis B Subjects Demonstrating Significant and Continuous Reductions in HBsAg"
https://finance.yahoo.com/news/arbutus-announces-ab-729-90-113000767.html
I still believe ABUS is a low-risk investment at under-$4 pps as a stand-alone...excluding...the absolute rocketship potential here if/WHEN it's "069-Patent" makes the 6:00 0'clock news...
ABUS 2.94 - "Arbutus Announces AB-729 90 mg Single-Dose Week 12 Data in Chronic Hepatitis B Subjects Demonstrating Significant and Continuous Reductions in HBsAg"
https://finance.yahoo.com/news/arbutus-announces-ab-729-90-113000767.html
Would love to hear comments on this update? I still believe ABUS is a low-risk investment at under-$4 pps as a stand-alone...excluding...the absolute rocketship potential here if/WHEN it's "069-Patent" makes the 6:00 0'clock news...
PENN 65.54 - kinda similar to the once unstoppable dot-bombs in that they're losing their arse but the future of 'internet-wagering' remains bright? I stopped trying to short(put) anything weeks ago as this market remains blind to most basic fundamentals...in layman speak...if ya can't beat em join em
VXRT 5.96 - "Vaxart Announces FDA Clearance of IND Application for Oral COVID-19 Vaccine and Provides Update on COVID-19 Program"
https://finance.yahoo.com/news/vaxart-announces-fda-clearance-ind-120000749.html
APT...It should make a move on the next spike in cases.
Either way, as the power-establishment would also overhype any decrease in cases as resultant of wearing masks? In patient hold mode and prepared to sit tight on my APT poke thru the next earnings report...
So I'll be anticipating a date of 9/9/20 for this Phase 1 clinical trial to commence? Will this upcoming event warrant a mention on the 6:00 o'clock news...
The government is “very pleased” with the progress, Health and Human Services deputy chief of staff Paul Mango said Friday afternoon. Mango is the agency's liaison with Operation Warp Speed, the White House-led task force on coronavirus vaccine and treatment development.
APT 14.70 - I added a few at 14.50 the other day...does look super-cheap with the enormous rev/eps growth. I'll be looking for 'Phase-2-Expansion' news much sooner than the next filing...
The Company continues to expect the phase 2 expansion of additional N-95 face mask manufacturing lines to be initially operational by the latter part of the third quarter of 2020. Once phase 2 is operational, the Company will further ramp up production throughout the remainder of 2020 and expects that for fiscal 2021 the production capacity for the N-95 face mask will be over $100 million.
https://finance.yahoo.com/news/correcting-replacing-alpha-pro-tech-190000045.html
The remaining two candidates will enter trials soon.
INO entered trials months ago...hence my reference to 'PROVEN also ran' and more clarity in my crystalball that INO is out of OWS
After reading this recent NEJM article...
https://www.nejm.org/doi/full/10.1056/NEJMp2027405?query=featured_home
...I'm really no longer feeling it here with INO.
One can argue that even without OWP, all covid-vaccine-stocks will remain in play for the foreseeable future and INO certainly has built up a sizeable cash warchest...but...one can counter-argue that INO is becoming more & more an outright PROVEN also-ran?
I'd be looking at puts on any future spike...
I found it in a wikipedia link:
https://en.wikipedia.org/wiki/Operation_Warp_Speed
And this is an interesting read:
The remaining two candidates will enter trials soon.
https://www.nejm.org/doi/full/10.1056/NEJMp2027405?query=featured_home
The link you provide makes no mention of Vaxart that I can see? Do you have a correct link?
SNFCA 6.44 - Net earnings per common share was $1.10 for the three months ended June 30, 2020, compared to net earnings of $0.19 per share for the prior year, as adjusted for the effect of annual stock dividends. Book value per common share was $11.87 as of June 30, 2020, compared to $10.86 as of December 31, 2019.
Just making sure that everyone got this memo...
TOMZ .765 - restarted a first position. Looking forward to an R/S and uplisting...
SOUTH SAN FRANCISCO, Calif., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that its COVID-19 Investigational New Drug (IND) application has been filed with the US Food and Drug Administration (FDA).
https://finance.yahoo.com/news/vaxart-announces-ind-filed-covid-120000578.html
From the FDA website:
An IND application may go into effect:
30 days after FDA receives the application, unless FDA notifies the sponsor that the investigations described in the application are subject to a Clinical Hold; or
on earlier notification by FDA that the clinical investigations in the IND may begin.
https://www.fda.gov/drugs/investigational-new-drug-ind-application/ind-application-procedures-overview
So I'll be anticipating a date of 9/9/20 for this Phase 1 clinical trial to commence? Will this upcoming event warrant a mention on the 6:00 o'clock news...